Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2

What is the survival benefit of risk-reducing mastectomy (RRM), independent of risk-reducing salpingo-oophorectomy (RRSO), among patients with pathogenic variants (PVs) in BRCA1 and BRCA2 genes? In this network meta-analysis of 5 observational studies with 7937 female patients, RRM was associated with a significant decrease in all-cause mortality compared with breast cancer screening with magnetic resonance imaging or mammography. The findings of this study suggest that RRM may provide survival benefit beyond that attributable to RRSO among patients with PVs in BRCA1 and BRCA2 genes and should remain a central component of individualized risk-reduction counseling.

Corresponding Author: J. Alejandro Rauh-Hain, MD, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Holcombe Blvd, Houston, TX 77030 (jarauh@mdanderson.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.